Clinical Trial Update: Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating dose-dense Adriamycin with Cytoxan followed by Abraxane or Taxol plus bevacizumab as adjuvant therapy in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Adriamycin (doxorubicin)
• Bevacizumab (bevacizumab)
• Cytoxan (cyclophosphamide)
• Taxol (paclitaxel)

Snippet

Sponsor: Celgene | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-07-18